Neoadjuvant therapy for HER-2 positive acantholytic squamous cell carcinoma of the breast: a case report
HER2-positive breast ASCC is exceptionally rare, its clinico pathological characteristics are insufficiently studied, and the im plications of neoadjuvant therapy, comprising targeted treatment against HER2. Here we reported that a 58-year-old woman with a histopathological diagnosis of HER2-positive ASCC gave a neo adjuvant therapy of albumin-paclitaxel, carboplatin in conjunction with trastuzumab every 3 weeks.